Advertisement

Pharmaceutical Research

, Volume 8, Issue 5, pp 584–587 | Cite as

Sustained Pharmacological Activities in Rats Following Single and Repeated Administration of Once-a-Month Injectable Microspheres of Leuprolide Acetate

  • Hiroaki Okada
  • Toshiro Heya
  • Yasuaki Ogawa
  • Hajime Toguchi
  • Tsugio Shimamoto
Article

Abstract

Once-a-month injectable microspheres of leuprolide acetate prepared with copoly(DL-lactic/glycolic acid) using an in-water drying method were assessed for duration of the analogue release and pharmacological effects in rats after a single or repeated injection. The periodic challenge test revealed that a single injection of the microspheres caused a dramatic and persistent suppression of the ability of the pituitary–gonadal system to secrete gonadotropin and testosterone for over 5 weeks. The complete recovery of these functions was observed 10 weeks after the injection. The repeated injection of the microspheres at intervals of 2 or 4 weeks achieved persistent suppression of steroidogenesis after an initial transient flare-up and beneficially avoided the “acute-on-chronic response.” This depot formulation is expected to assure patient compliance and produce stronger therapeutic effects than the daily solution.

leuprolide (leuprorelin) once-a-month injectable microspheres gonadotropin suppression steroidogenesis inhibition repeated administration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    H. Okada. One-month release injectable microspheres of leuprolide acetate, a superactive agonist of LH-RH. Proc. Int. Symp. Control. Rel. Bioact. Mater. 16:12–13 (1989).Google Scholar
  2. 2.
    H. Okada, T. Heya, Y. Igari, M. Yamamoto, Y. Ogawa, H. Toguchi, and T. Shimamoto. One-month release injectable microspheres of a superactive agonist of LH-RH, leuprolide acetate. In D. Marshak and D. Liu (eds.), Therapeutic Peptides and Proteins; Formulation, Delivery, and Targeting, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989, pp. 107–112.Google Scholar
  3. 3.
    E. S. Johnson, J. H. Seely, W. F. White, and E. R. DeSombre. Endocrine-dependent rat mammary tumor regression: Use of a gonadotropin releasing hormone analog. Science 194:329–330 (1976).Google Scholar
  4. 4.
    T. W. Redding and A. V. Schally. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 78:6509–6512 (1981).Google Scholar
  5. 5.
    H. Okada, Y. Sakura, T. Kawaji, T. Yashiki, and H. Mima. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally. Cancer Res. 43:1869–1874 (1983).Google Scholar
  6. 6.
    A. Lemay and G. Quesnel. Potential new treatment of endometriosis: Reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil. Steril. 38:376–379 (1982).Google Scholar
  7. 7.
    H. Okada, M. Yamamoto, Y. Ogawa, T. Yashiki, and T. Shimamoto. Controlled-release injectable microcapsules of leuprolide (1): Biodegradation of polymer wall materials and drug release (abstract). The 105th Annual Meeting of Pharmaceutical Society of Japan, Kanazawa, 1985, p. 790.Google Scholar
  8. 8.
    H. Okada, Y. Ogawa, and T. Yashiki. Prolonged release microcapsules and their production. U.S. Patent 4652441 (1987).Google Scholar
  9. 9.
    Y. Ogawa, M. Yamamoto, H. Okada, T. Yashiki, and T. Shimamoto. A new technique to efficiently entrap leuprolide acetate into microcapsules polylactic acid or copoly(lactic/glycolic) acid. Chem. Pharm. Bull. 36:1095–1103 (1988).Google Scholar
  10. 10.
    H. Okada, T. Heya, Y. Igari, Y. Ogawa, H. Toguchi, and T. Shimamoto. One-month release injectable microspheres of leuprolide acetate inhibit steroidogenesis and genital organ growth in rats. Int. J. Pharm. 54:231–239 (1989).Google Scholar
  11. 11.
    Y. Ogawa, H. Okada, T. Heya, and T. Shimamoto. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly (lactic/glycolic) acids and in vivo degradation of these polymers. J. Pharm. Pharmacol. 41:439–444 (1989).Google Scholar
  12. 12.
    H. Okada, T. Heya, Y. Ogawa, and T. Shimamoto. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther. 244:744–750 (1988).Google Scholar
  13. 13.
    L. M. Sanders, J. S. Kent, G. I. McRae, B. H. Vickery, T. R. Tice, and D. H. Lewis. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres. J. Pharm. Sci. 73:1294–1297 (1984).Google Scholar
  14. 14.
    T. W. Redding, A. V. Schally, T. R. Tice, and W. E. Meyers. Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of (D-Trp6) luteinizing hormone-releasing hormone from injectable microcapsules. Proc. Natl. Acad. Sci. USA 81:5845–5848 (1984).Google Scholar
  15. 15.
    K. J. Catt, A. J. Baukal, T. F. Davies, and M. L. Dufau. Luteinizing hormone-releasing hormone-induced regulation of gonadotropin and prolactin receptors in the rat testis. Endocrinology 104:17–25 (1979).Google Scholar
  16. 16.
    B. S. Conne, S. Scaglioni, U. Lang, P. C. Sizonenko, and M. L. Aubert. Pituitary Receptor sites for gonadotropin-releasing hormone: Effect of castration and substitutive therapy with sex steroids in the male rat. Endocrinology 110:70–79 (1982).Google Scholar
  17. 17.
    C. Rivier, J. Rivier, and W. Vale. Antireproductive effects of a potent gonadotropin-releasing hormone antagonist in the male rat. Science 210:93–95 (1980).Google Scholar
  18. 18.
    R. Bodmeier and J. W. McGinity. Polylactic acid microspheres containing quinidine base and quinidine sulfate prepared by the solvent evaporation technique. II. Some process parameters influencing the preparation and properties of microspheres. J. Microcapsul. 4:289–297 (1987).Google Scholar
  19. 19.
    H. Okada, I. Yamazaki, Y. Sakura, T. Yashiki, T. Shimamoto, and H. Mima. Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats. J. Pharm. Dyn. 6:512–522 (1983).Google Scholar

Copyright information

© Plenum Publishing Corporation 1991

Authors and Affiliations

  • Hiroaki Okada
    • 1
  • Toshiro Heya
    • 1
  • Yasuaki Ogawa
    • 1
  • Hajime Toguchi
    • 1
  • Tsugio Shimamoto
    • 1
  1. 1.Pharmaceutics Research LaboratoriesTakeda Chemical Industries, Ltd.YodogawaJapan

Personalised recommendations